Century Therapeutics, Inc. (IPSC) experienced an increase of 6.98% in aftermarket. However, the last trading session closed at $17.2 with a decline of 4.18%.
Piper Sandler 33rd Annual Virtual Healthcare Conference – When is it?
IPSC announced on 22nd November 2021 that the senior members from management will take part in the Piper Sandler 33rd Annual Virtual Healthcare Conference. The conference will occur from 30th November – 2nd December 2021.
Third Quarter Results 2021 by IPSC – What are the new updates?
On 10th November 2021, IPSC reported third-quarter 2021 results. According to the company, the cash and cash equivalents came out to be $400.3 million. Moreover, the research and development costs were $19.5 million and general and administrative costs were $19.5 million. Lastly, the net loss was $26 million compared to $13.1 million for the same period in 2020.
Now what?
IPSC proceeded to intensify the investment opportunities in cellular reprogramming, genetic engineering, and production. This will be helpful to advance the iPSC platforms. Moreover, this was done with the intention to develop treatments that can substantively advance cancer care.
In addition, as part of the aim to establish a next-generation cell treatment platform, the company is investing in new technologies through the recently announced cooperation with Outpace Bio. Later this year, and at the future virtual research and development update, the company plans to share scientific updates on the initiatives.
Research Collaboration by IPSC – what’s happening?
On 7th October 2021, IPSC announced the research collaboration in CAR engineering. By merging Outpace’s optimized CAR spacer technology with Century’s VHH domain binders, the cooperation will combine Century’s CAR and protein engineering skills with Outpace’s protein design and synthetic biology capabilities to boost CAR functioning.
As an emerging leader in iPSC-based cell therapy, investing in cutting-edge cell engineering technology is key to developing breakthrough next-generation allogeneic cell therapeutics. In addition, the agreement with Outpace will strengthen the protein engineering skills and may speed up the development of unique next-generation CARs.
What’s Next?
IPSC happily works to generate highly optimized CARs for their promising iPSC-based cell treatments. This cooperation provides the perfect opportunity to speed up the effect of Outpace’s spacer technology. This would be part of the wider strategy to create T cell therapies, and Outpace’s protein design capabilities. Hence, it allows offering improved capabilities and flexibility to Century’s iPSC platform and product candidates.
